IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection

Maureen P. Martin, Ying Qi, James J. Goedert, Shehnaz K. Hussain, Gregory D. Kirk, W. Keith Hoots, Susan Buchbinder, Mary Carrington, Chloe L. Thio

Research output: Contribution to journalArticlepeer-review


An IL28B haplotype strongly determines the outcome of natural and interferon-α treated hepatitis C virus (HCV) infection. To assess whether the polymorphism marking the haplotype (rs12979860) also affects other interferon-α responsive chronic viral illnesses, namely hepatitis B virus (HBV) and human immunodeficiency virus (HIV) type 1 infections, we genotyped 226 individuals with HBV persistence, 384 with HBV recovery, and 2548 with or at high risk for HIV infection. The C/C genotype of rs12979860 was not associated with HBV recovery (odds ratio, 0.99), resistance to HIV infection (odds ratio, 0.97), or HIV disease progression (P > .05). This IL28B single-nucleotide polymorphism affects the immune response to HCV but not to HBV or HIV.

Original languageEnglish (US)
Pages (from-to)1749-1753
Number of pages5
JournalJournal of Infectious Diseases
Issue number11
StatePublished - Dec 1 2010

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases


Dive into the research topics of 'IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection'. Together they form a unique fingerprint.

Cite this